0000000000890710

AUTHOR

Suzanne C. Cannegieter

0000-0003-4707-2303

showing 1 related works from this author

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

2018

Abstract Background Prediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain. Objective To assess the influence of rivaroxaban and apixaban on several coagulation factor levels. Methods In two crossover trials we assessed the influence of rivaroxaban and apixaban intake on factor (F)VIII, FXI and FXII‐activity and fibrinogen, von Willebrand factor (VWF:Ag), and d‐dimer levels. At three sessions with a washout period in between, blood was taken from 12 healthy male individu…

medicine.medical_specialtymedicine.drug_mechanism_of_actionFactor Xa Inhibitorapixabanfactor Xa inhibitors030204 cardiovascular system & hematologyTreatment resultsFibrinogenGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorInternal medicinecoagulantsMedicinerivaroxabanBlood coagulation testRivaroxabanbiologybusiness.industryBrief Reportblood coagulation testsrisk assessmentHematologyCoagulation030220 oncology & carcinogenesisbiology.proteinApixabanbusinessOriginal Articles: Thrombosismedicine.drug
researchProduct